Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children
| Authors | |
|---|---|
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská neurologie a neurochirurgie |
| MU Faculty or unit | |
| Citation | |
| Field | Other medical specializations |
| Keywords | S100protein; severe head injury; outcome; children |
| Description | S100B is a protein biomarker that reflects CNS injury. The aims of the current study were to investigate correlations between the initial level of serum S100B protein and mortality and computerized tomography (CT) findings, as well as to establish whether there is an association between S100B and Glasgow outcome scale (GOS) after six months. This prospective study enrolled 43 patients with traumatic brain injury (TBI), verified by computerized tomography and categorized by Marshall classification. Venous blood samples were taken on admission and every 24 h for a maximum of six consecutive days. The outcome was evaluated six months after TBI using the Glasgow outcome scale (GOS) in all patients. GOS was taken as principal end point for all predictive analyses. We demonstrated statistically significant relationships between groups of patients and increased incidence of some types of injury – intracranial bleeding, subdural haematoma, skull fracture, and oedema. The ratio of S100B in 2nd day/initial S100B value significantly differentiated between the groups of patients compared. Levels of S100B were elevated in patients with some specific types of injury, namely intracranial bleeding, subdural haematoma and oedema. The level of S100B was confirmed as a clinically valuable indicator of severity of injury and is proposed as an effective predictor of risk outcome (GOS = 1). |